Statins May Be Safe for Some Lymphoma Patients

Patients with follicular lymphoma may be able to safely use statins, according to a new study published in the American Journal of Hematology.

Rituxmab, a drug often prescribed for follicular non-Hodgkin's lymphoma, has had a negative association with statins in laboratory experiments, according to Lymphoma News Today. However, the new research suggests the two drugs do not worsen a patient's condition.

The research was conducted at Claude Bernard University Lyon in France, where 1,135 patients were studied for adverse effects and overall survival while taking statins, rituxmab, or both of these medications.

Statins and cancer

A large body of research suggests that statins are linked to an increased risk of various types of cancer or worsening of tumors, especially in patients with breast or prostate cancer.

However, the current study found no differences in survival rates or adverse effects between patients taking just rituxmab or both rituxmab and statins.

"The rates of overall and specific cardiovascular adverse events between the 2 groups of patients were comparable both during induction and maintenance," the study authors wrote.

Source: Lymphoma News Today, Healthline

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap